Transition of ADHD from Adolescence to Adulthood
The UK Adult ADHD Network (UKAAN) will hold the 3rd Congress on the 29th June 2012. The theme will be ‘Transition of ADHD from Adolescence to Adulthood’. The conference will be located in Central London in a beautiful venue overlooking the River Thames.
The congress aims to bring important topics on transition in ADHD to a wider audience. The scientific program will include five main sessions, with a panel and audience discussion
Clinical services for ADHD during the transition years from adolescence to adulthood and for those newly diagnosed as adults are developing rapidly. This meeting will address important clinical and scientific questions relating to ADHD and will be relevant to anyone interested in the mental health of people from the adolescent years through to early, middle and later adult life.
ADHD is a common mental health disorder that starts during child development but frequently persists throughout adolescence and into the adult years. Common symptoms include inattention, distractibility, disorganisation, overactivity, restlessness, impulsiveness and mood instability; and these may lead to considerable clinical and psychosocial impairments. ADHD is often seen at a high rate in people with other significant clinical problems including substance abuse, unstable mood states, anxiety, depression, forensic cases and emerging or developed personality disorder.
Despite the considerable psychiatric morbidity associated with ADHD and the availability of effective pharmacological and non-pharmacological treatments, the disorder often goes unrecognised and untreated in people as they grow older. This leads to unnecessary distress to individuals, ineffective targeting of treatments, poor control over chronic mental health problems and the development of adult onset disorders later in life.
This meeting aims to raise the level of awareness and knowledge among health care professionals about people with ADHD as they grow older; and to provide a better understanding of the causal pathways involved in the persistence of the disorder and the development of important clinical comorbidities.
Professor Philip Asherson